contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


new-shares-issued-in-revenios-directed-share-issue-have-been-registered-with-the-finnish-trade-register

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand.

In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Caravelle Capital SAS has been gobbling up shares, their stake is now 5.22%: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus omistusosuuden muutoksesta | Kauppalehti Aha, these were likely the shares from the directed share issue to the French. However, the release mentions: “The person subject to the notification obligation is not controlled by any natural person or legal entity, nor does the person subject to the notification obligation have any controlled entities that hold a direct or indirect interest in the target company.”

Here are @Juha_Kinnunen’s comments on the closing of the Visionix deal: Revenio: Visionix-kauppa maaliin hieman odotettua nopeammin - Inderes Personally, I’ve been thinking that before the Q2 earnings release on August 6th, the share price will fluctuate between €13.50 and €14.50. In any case, the rights issue (merkintäanti) to be held later this year is looming in the background; experts estimate the price at €13, with approximately 6 million new shares being printed then. Of course, traders will try to test the price below €13, but buying pressure will be found there at the latest. Shorters won’t dare risk the Q2 release, as we will get new consolidated figures for the combined Revenio-Visionix entity and there could be positive surprises—and above all, we will receive guidance.

Hi, Funny to see how many of you speak about lazzy French workers. Tell OECD: https://www.oecd.org/en/publications/oecd-compendium-of-productivity-indicators-2025_b024d9e1-en/full-report/cross-country-comparisons-of-labour-productivity-levels_b2fdb493.html#title-92789e087c I am going back to my croissants

Deal closed. Will we start seeing insider buying now? Revenio completes the acquisition of Visionix and has decided on a directed share issue as part of the payment of the purchase price - Inderes

Thanks for the answer. I’ve probably been involved for 20+ years myself, dating back to the Done “general store” days. Now it feels like we’re heading back in that direction instead of keeping a sharp focus on eye diagnostics! Simply buying an OCT would have suited me best—ideally years ago, when I even tried to clarify that need to the management. Revenio’s valuation was something quite different back then. If we had paid for quality, even at a premium using shares and cash, the growth in earnings and brand value would have taken care of it by now, and the share price might be something else entirely. Well, the cards have been dealt, we’ll play with what we have, but to me, this doesn’t look like a winning hand. A shame.

I have also been involved for a long time, 20+ years. What would have been Revenio’s alternative? Continue as is, distribute the funds as dividends? Just OCT? By acquiring or developing in-house? Some other way to expand or invest? Perhaps the same margins are no longer available, but the risk is also lower. Lower risk always means lower margins, but more certain income. Revenio is now pushing multiple roots of growth into a familiar market. Otherwise, the risks would have started to become too great. Revenio is growing into the Illodin or pop-rivet of the ophthalmology field—meaning Revenio becomes a generic term for good eye care… For me, the most interesting option would have been to sell the whole business at ATH (All-Time High) prices. That is still not off the table. Another option would have been to look at a completely new industry and product, but that’s too risky. Close to eyes would be, for example, ears, hearing, and their care chain. There is still a lot to be done in that area. Previous acquisitions have remained somewhat mysterious. Hopefully, they weren’t reckless spending, but rather that something great grows from the whole, as I trust it will. Many have been doubting lately.

I have followed the tightening competition in the optical industry for over 30 years. Stores are being closed, customer service staff is being reduced, there is a constant rush, and set profit targets must be met. I do not believe that they can get anywhere near Revenio’s current margin levels. You are right, customers are loyal to a good optician just as they are to a good doctor. An optician’s work in fitting frames and lenses is more important than the amount of money spent on the glasses; even expensive lenses won’t work if the fitting is done sloppily, while a functional result can be achieved even with cheap solutions. First came laser treatments—distance vision corrected without glasses, and reading glasses (+2€) from the supermarket. Then came lens surgeries, where a multifocal IOL (intraocular lens) replaces one’s own crystalline lens, often allowing people to get by without any glasses at all, with no fear of cataracts in old age. All of this also affects optical sales. When I invested family funds into Done/Revenio over 15 years ago, I was able to understand the potential of iCare. Now, unfortunately, I don’t see the potential for high-margin returns in this “optical nonsense,” though revenue and administrative costs will certainly grow. Please explain, if you understand the matter better. I truly hope I am wrong. Have a peaceful holiday.

Revenio Group

Revenio Group Corporation | Stock Exchange Release | May 29, 2026 at 09:45:00 EESTA total of 2,485,797 new shares issued in the share issue directed to Visionix shareholders, as announced by...

<div class="mfn-header mfn-header-finland">Revenio Group Corporation | Stock Exchange Release | May 29, 2026 at 09:45:00 EEST</div><div class="mfn-body">A total of 2,485,797 new shares issued in the share issue directed to Visionix shareholders, as announced by Revenio Group Corporation on 28 May 2026, have been registered today, 29 May 2026, in the Finnish Trade Register. After the registration of the new shares, Revenio has a total of 29,166,913 shares.The new shares will confer equal rights to the company’s existing shares from the date of registration.The new shares will be admitted to trading on Nasdaq Helsinki Ltd’s main list approximately from June 1, 2026 onwards.For further information, please contact CEO Jouni Toijala, tel. +358 484 0085 <a href="mailto:jouni.toijala@revenio.fi" rel="noopener">jouni.toijala@revenio.fi</a>Distribution Nasdaq Helsinki Oy Financial Supervisory Authority (FIN-FSA) Main media <a href="http://www.reveniogroup.fi/en" rel="noopener">www.reveniogroup.fi/en</a>Revenio Group in brief Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.&nbsp;In May 2026, Revenio joined forces with Visionix,&nbsp;creating&nbsp;the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology.&nbsp;In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.&nbsp;</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/8d7c7894-038d-477d-999a-4e6b3d904989/new-shares-issued-in-revenios-directed-share-issue-have-been-registered-with-the-finnish-trade-register.pdf" rel="noopener">New shares issued in Revenio’s directed share issue have been registered with the Finnish Trade Register</a></div>